The most common mutations are IDH1 R132 and IDH2 R172, comprising roughly 90% of IDH mutations; the former is noted in more than 70% of grade 2/3 gliomas and in GBMs that progressed from these lower-grade tumors [41,43]. This evidence concerns the gene IDH2 and central nervous system cancer.